Ipsita Roymoulik, PhD

Over 20 years of CMC expertise supporting clinical development of oligonucleotide, mRNA and cell therapy drugs. Breadth in analytical development, process development and quality assurance within contract manufacturing and drug innovation organizations. Previously contributed to 2 BLAs and dozens of client INDs at Avecia and Moderna’s first 10 INDs.